Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
暂无分享，去创建一个
L. Carey | W. Symmans | M. Goetz | N. Tung | K. Ballman | V. Borges | A. Partridge | T. Zemla | L. Mccall | I. Krop | A. Weiss | Myounghee Lee | C. O'Sullivan | W. Irvin | V. Blinder | Anuhya Kommalapati | M. Mitchell | Tyler Zemla